Zeller J C, Panoskaltsis-Mortari A, Murphy W J, Ruscetti F W, Narula S, Roncarolo M G, Blazar B R
Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis 55455, USA.
J Immunol. 1999 Oct 1;163(7):3684-91.
Induction and maintenance of Ag-specific tolerance are pivotal for immune homeostasis, prevention of autoimmune disorders, and the goal of transplantation. Recent studies suggest that certain cytokines, notably IL-10 and TGF-beta, may play a role in down-regulating immune functions. To further examine the role of cytokines in Ag-specific hyporesponsiveness, murine CD4+ T cells were exposed ex vivo to alloantigen-bearing stimulators in the presence of exogenous IL-10 and/or TGF-beta. Primary but not secondary alloantigen proliferative responses were inhibited by IL-10 alone. However, the combined addition of IL-10 + TGF-beta markedly induced alloantigen hyporesponsiveness in both primary and secondary MLR cultures. Alloantigen-specific hyporesponsiveness was observed also under conditions in which nominal Ag responses were intact. In adoptive transfer experiments, IL-10 + TGF-beta-treated CD4+ T cells, but not T cells treated with either cytokine alone, were markedly impaired in inducing graft-vs-host disease alloresponses to MHC class II disparate recipients. These data provide the first formal evidence that IL-10 and TGF-beta have at least an additive effect in inducing alloantigen-specific tolerance, and that in vitro cytokines can be exploited to suppress CD4+ T cell-mediated Ag-specific responses in vivo.
诱导和维持抗原特异性耐受对于免疫稳态、预防自身免疫性疾病以及移植目标至关重要。最近的研究表明,某些细胞因子,尤其是白细胞介素-10(IL-10)和转化生长因子-β(TGF-β),可能在下调免疫功能中发挥作用。为了进一步研究细胞因子在抗原特异性低反应性中的作用,将小鼠CD4+ T细胞在体外于外源性IL-10和/或TGF-β存在的情况下暴露于携带同种异体抗原的刺激物。单独的IL-10抑制初次而非二次同种异体抗原增殖反应。然而,IL-10 + TGF-β的联合添加在初次和二次混合淋巴细胞反应(MLR)培养中均显著诱导同种异体抗原低反应性。在名义抗原反应完整的条件下也观察到了同种异体抗原特异性低反应性。在过继转移实验中,经IL-10 + TGF-β处理的CD4+ T细胞,而非单独用任何一种细胞因子处理的T细胞,在诱导对MHC II类不相合受体的移植物抗宿主病同种异体反应方面明显受损。这些数据提供了首个正式证据,即IL-10和TGF-β在诱导同种异体抗原特异性耐受方面至少具有相加作用,并且体外细胞因子可用于在体内抑制CD4+ T细胞介导的抗原特异性反应。